secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edesa Biotech, Inc. (EDSA)
CIK:        0001540159
Form:       8-K
Filed at:   2025-02-14T23:59:59+00:00
Accession:  0001171843-25-000864
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edesa Biotech reports Q1 FY2025 net loss of $1.6M; raises $15M in private placement
--------------------------------------------------------------------------------

- Net loss of $1.6M ($0.48/share) compared to $1.7M ($0.54/share) in prior year quarter.
- R&D expenses rose to $1.0M (from $0.7M) on increased manufacturing costs for paridiprubart.
- Cash at Dec 31, 2024 was $1.6M; subsequent $15M preferred/common private placement closed.
- Company plans IND for EB06 (anti-CXCL10) in vitiligo Phase 2; FDA submission mid-2025.
- EB05 (paridiprubart) ARDS study fully funded by U.S. government; top-line vitiligo data expected within 12-18 months post clearance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540159/000117184325000864/0001171843-25-000864-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540159/000117184325000864/f8k_021425.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-000864

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer